21-063 - Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLLStatus: open
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Treatment for Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.
Interested in Clinical Trial?
Providers Associated With This Trial
- Omar Alkharabsheh, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology
- Brian E. Persing, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology